KLK5 and urogenital neoplasm: On the other hand, higher levels of KLK5 expression were detected more frequently in less aggressive forms of prostate tumors [19,20], while recent findings have demonstrated the clinical use of KLK5 expression as a biomarker for the prediction of prostate patients' response to chemotherapy [21,22].